MedTrace Logo

A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of the Blood-stage Malaria Candidate Vaccines RH5.1 in Matrix-M and R78C in Matrix-M in Healthy UK Adults

NCT05385471 · Status: ACTIVE_NOT_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2025-04-01

No results posted yet for this study

Summary

This is an open-label, single-centre Phase I P. falciparum blood-stage vaccine trial to assess the safety and immunogenicity and efficacy of the candidate malaria vaccines R78C and RH5.1 formulated in adjuvant Matrix-M

Conditions

  • Malaria, Falciparum

Interventions

BIOLOGICAL

Matrix M with R78C and/or RH5.1

50 µg of Matrix-M adjuvant with R78C and/or RH5.1 at different doses and timepoints

Sponsors & Collaborators

  • University of Oxford

    lead OTHER

Principal Investigators

  • Angela M Minassian, DPhil FRCP · Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, United

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-01-13
Primary Completion
2026-03-31
Completion
2026-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05385471 on ClinicalTrials.gov